Board MeetingMay 27, 2026, 04:02 PM
Cytokinetics to Participate in June Investor Conferences
AI Summary
Cytokinetics, Incorporated announced that its management team will participate in two upcoming investor conferences in June. These include a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and another at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Live webcasts and replays will be available on the company's investor relations website. Cytokinetics is a cardiovascular biopharmaceutical company with an approved product, MYQORZO (aficamten), and a pipeline of investigational medicines.
Key Highlights
- Cytokinetics management to participate in the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 8:10 AM ET.
- Company management to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 9:20 AM ET.
- Live webcasts of the fireside chats will be accessible via the Investors & Media section of the Cytokinetics website.
- Webcast replays will be archived on the Cytokinetics website for 90 days post-event.
- Cytokinetics is a specialty cardiovascular biopharmaceutical company.
- MYQORZO (aficamten) is approved in the U.S., Europe, and China for obstructive hypertrophic cardiomyopathy (oHCM).
- Company is preparing to present full ACACIA-HCM Phase 3 results for aficamten in non-obstructive HCM.
Price Impact
More from CYTK